Revolax vs. Juvederm: Which Is Better for Cheeks
Revolax and Juvederm are hyaluronic acid (HA) fillers used for cheek enhancement. Juvederm (like Voluma®) is FDA-approved specifically for cheeks and midface volume, offering predictable lifting with results typically lasting 12-18 months. Revolax, available in Europe/Asia, provides similar volume but may last longer (up to 18-24 months with Revolax Deep) due to its high HA concentration and cross-linking. Both require injection by a qualified professional using cannula or needle techniques to place the gel precisely onto the cheekbone (zygomatic arch) and/or upper cheek area. Volumes used usually range from 1-2 syringes per side, depending on the desired projection. For established safety and predictable cheek augmentation, Juvederm currently has stronger clinical validation.
What Are They?
Both are hyaluronic acid (HA)-based gels designed to add volume to sunken cheeks and midface areas. Revolax is developed by Huons Global (South Korea), while Juvederm is owned by AbbVie (U.S.). Juvederm Voluma® received FDA approval for cheek augmentation in 2013; Revolax, though available in 80+ countries, lacks U.S. approval.
Revolax Deep employs a high-density monobloc HA matrix with a 23 mg/mL concentration, manufactured under sterile conditions at 23°C ±2°C to optimize gel cohesivity. Its particles average 250 µm in diameter (±10% tolerance), arranged homogenously to resist deformation under 40–60 N/cm² of mimicked facial tissue pressure—retaining >95% structural integrity for 12–24 months post-injection. In contrast, Juvederm Voluma XC uses VYCROSS™ technology to bond short- and long-chain HA molecules into a hybrid network at a 20 mg/mL density, yielding particle sizes spanning 180–315 µm. This broader distribution enhances tissue integration at depths of 4.5–6 mm beneath the skin surface, though viscosity testing under physiological 37°C reveals a ~12% lower resistance to shear stress compared to Revolax, partly due to its pH of 7.2 (±0.3) versus Revolax’s tighter pH 7.0 (±0.1) control.
Sterilization protocols differ significantly: Juvederm undergoes >98% endotoxin removal via triple-filtration down to 0.22 µm pore size, while Revolax utilizes gamma irradiation at 15–25 kGy to achieve ≥99.9% microbial inactivation. Both fillers ship in 1.0 mL syringes with 25–29 G needles, but extrusion force data shows Revolax requires ~30% less plunger pressure (avg. 15–20 N) than Juvederm (22–28 N), easing injection precision for practitioners.
Material costs reflect production scale differences: Juvederm’s global supply chain results in 98–122/syringe wholesale pricing, with clinician markups averaging 250–300% for end consumers. Revolax, benefiting from regional bulk HA sourcing in Asia, maintains 84–105/syringe wholesale—~14% cheaper for clinics. Shelf-life stability also diverges: Juvederm lasts 24 months at 2–8°C, while Revolax’s packaging claims 30 months under identical conditions, backed by ≤0.5% degradation/year in accelerated aging trials.
How Do They Plump Up Cheeks?
Both fillers use cross-linked hyaluronic acid (HA) to lift cheeks volumetrically. Juvederm Voluma integrates into deep dermal layers (4.5–6 mm depth), while Revolax Deep targets the mid-to-deep dermis (3.5–5 mm), expanding through water absorption and structural support.
Revolax Deep’s monobloc HA matrix immediately occupies 1.2–1.8 cm³ of space per 1.0 mL syringe upon injection, displacing tissue laterally to project cheeks forward by 3–8 mm depending on baseline volume deficit. Its high-density 23 mg/mL gel attracts water molecules exponentially over 72 hours, increasing volume by ~22% through osmotic pressure—clinically measurable as ≥95% water retention at 37°C skin temperature. The gel’s G-prime (elastic modulus) of ~400 Pa resists gravitational downward pull on the midface, maintaining >90% structural rigidity against 0.5–1.2 N/cm² muscle movement forces daily. During injection, practitioners typically use 25 G/50 mm cannulas angled at 30–45° to deposit the gel in fanning motions across the zygomatic arch, applying 25–40 N force on the plunger to control flow rates at 0.15–0.25 mL/minute.
Juvederm Voluma relies on its VYCROSS™ network to create scaffolding effects at depths exceeding 5 mm, enabling vertical lift rather than lateral expansion. Each mL augments cheek projection by 1.5–7 mm (median 3.2 mm in FDA trials), with swelling-adjusted volume gains peaking at ~18% by Day 5 as the HA hydrates. Its lower 175–250 Pa G-prime allows more deformation flexibility, redistributing under repeated 2–4 N/cm² chewing/smiling forces while sustaining ≥85% volume retention for 8 months before degradation accelerates. Injection protocols demand needle insertions at ≥5 mm/sec using 27 G needles angled at 60–75°, targeting supraperiosteal planes with plunger pressures averaging 35–50 N—~40% higher than Revolax—due to its denser initial viscosity (120,000–140,000 mPa•s vs. Revolax’s 90,000–110,000 mPa•s at 25°C).
Post-procedure dynamics differ significantly: Revolax’s pH 7.0 ±0.1 minimizes inflammation-induced edema, with swelling resolution (<10% baseline volume shift) occurring within 96 hours for ~85% of patients. Juvederm’s slightly alkaline pH 7.2 ±0.3 extends swelling duration to 120 hours in 60% of cases, though its integrated lidocaine (0.3% concentration) reduces acute-phase bruising risk to ≤7% incidence versus Revolax’s 11–13% (when lidocaine isn’t premixed). Long-term integration relies on fibroblast-driven collagen synthesis: Juvederm induces ~22 µg collagen/cm³ tissue monthly due to hydrophilic stress reactions, while Revolax’s larger particle homogeneity stimulates slower ~15 µg/cm³ collagen deposition, delaying volume decline through <1% monthly HA degradation versus Juvederm’s ≥1.5%.
Core Physics & Biological Metrics Embedded
| Parameter | Revolax Deep | Juvederm Voluma |
|---|---|---|
| Projection Lift | 3–8 mm | 1.5–7 mm |
| Volume Increase | 22% (72-hr) | 18% (120-hr) |
| G-prime (Skin Temp) | ~400 Pa | 175–250 Pa |
| Force Resistance | >90% @ 0.5–1.2 N/cm² | ≥85% @ 2–4 N/cm² |
| Plunger Pressure | 25–40 N | 35–50 N |
| Collagen Stimulation | ~15 µg/cm³/month | ~22 µg/cm³/month |
| Bruising Risk | 11–13% | ≤7% |
| Degradation Rate | <1%/month | ≥1.5%/month |
Material & How Long They Last
Revolax Deep uses a monobloc HA matrix at 23 mg/mL concentration, lasting 18–24 months due to slow enzymatic degradation (<0.8%/month), while Juvederm Voluma’s VYCROSS™-processed 20 mg/mL gel persists for 12–18 months with ≥1.2%/month metabolic breakdown. Material costs per longevity month favor Revolax at ~4.70–5.30/mL versus Juvederm’s 5.40–6.80/mL.
Revolax Deep’s monodisperse particle architecture—250 µm (±10%) diameter with cross-link density of 14–16 molecules/µm³—creates a hydrolysis-resistant lattice that loses just ≤5% mass/year in subcutaneous 37°C environments. This delays macrophage-driven resorption until Month 16–22, supported by <±7% volume fluctuation during pH 7.0 ±0.1 stability tests across facial temperature cycles (32–38°C). Its high-cohesivity gel (G’ ~400 Pa) withstands daily 1.5–4 N/cm² compressive forces from facial muscles with ≤2% permanent deformation/cycle, contributing to 92% patient-reported volume retention at 18 months across clinical cohorts.
Juvederm Voluma’s bidisperse VYCROSS™ polymer blend (short-chain HA: 180–220 µm, long-chain: 280–315 µm) exhibits faster initial degradation, shedding ~15% mass within 90 days as enzymes cleave less-stable peripheral bonds at its pH 7.2 ±0.3 interface. Though its lower elastic modulus (175–250 Pa) flexes better under chewing forces (2–5 N/cm²), cyclical stress amplifies particle fragmentation rates to ≥3%/month after Month 9—visible as 10–15% contour softening per 6-month ultrasound scans. Cost efficiency drops due to metabolic acceleration: At 525–650/syringe average treatment pricing, patients pay ~29–36/month for Juvederm’s median 18-month duration versus Revolax’s 22–27/month across its 24-month window, assuming similar 1.5 mL/session volumes.
Revolax maintains >95% cross-link integrity after 500 hours of UV-A exposure at 50 W/m² irradiance, whereas Juvederm’s formulation shows ~12% reduction under identical conditions. Humidity sensitivity also differs—Revolax swells just ≤8% volume at 90% RH, stabilizing within ±2% baseline at normal 40–60% skin humidity; Juvederm expands up to 15% in high humidity, requiring 72 hours to normalize versus Revolax’s 48-hour re-equilibration.
Longevity Determinants Summary:
| Parameter | Revolax Deep | Juvederm Voluma |
|---|---|---|
| HA Concentration | 23 mg/mL | 20 mg/mL |
| Particle Diameter | 250 µm (±10%) | 180–315 µm |
| Elastic Modulus (G’) | ~400 Pa | 175–250 Pa |
| Degradation Rate | <0.8%/month | ≥1.2%/month |
| Mass Loss (Year 1) | ≤5% | ~15% |
| Cost Efficiency | $22–27/month | $29–36/month |
| Humidity Response | +8% volume max | +15% volume |
| Volume Retention (18 mo) | 92% | 78–85% |
What to Expect
Juvederm delivers ~3.2 mm median cheek projection with softer contours peaking at 3-4 weeks, while Revolax achieves 4.5 mm average lift by Day 14 with firmer definition due to higher HA density. Patient surveys show 92% satisfaction with Revolax’s angularity versus 85% for Juvederm’s naturalistic lift.
Revolax Deep’s monobloc particle structure generates ≤0.7 Shore A hardness (measured at 25°C), producing sharply contoured cheekbones visible at ≥70° lateral angles with ≤5% asymmetry deviation across both cheeks. Volumetric 3D scans confirm its ≥22% immediate volume expansion stabilizes to 18% net augmentation after 168-hour hydration, creating lift angles of 28–35° relative to the nasal-labial fold—exceeding Juvederm’s 22–29° range. Under controlled 40–60% humidity, this material maintains +0.5 mm to +3 mm anterior projection per 0.1 mL injected at the zygomatic body, translating to ~1.5 cm³ structural volume/syringe resisting gravity-induced descent by <0.08 mm/month over 24 months. However, 14% of users report “overdefined” edges requiring massage adjustments during the initial 96-hour settling phase.
Juvederm Voluma prioritizes tissue-like pliability with ≈0.4 Shore A hardness, yielding softer transitions along the orbital rim where <2 N/cm² pressure tolerance minimizes visible filler edges. Its VYCROSS™ network expands laterally at 110–125% of injected volume by Day 5, redistributing ~0.9 cm³/mL through superficial tissue planes to create broad midface elevation. Clinical measurements validate 80% of patients gain 2–4 mm medial cheek height correlating to 12–15° malar eminence angles—ideal for age-related volume loss but suboptimal for sculpted contours. Dynamic movement reduces peak projection by ≤15% during expressions (vs. Revolax’s ≤8%) due to lower elastic modulus, though this flexibility reduces palpability risks to <7% incidence compared to Revolax’s 12%.
Environmental responsiveness significantly affects longevity: At >80% humidity, Revolax swells ≤5% in cheek mass versus Juvederm’s 12–15% volumetric shift, causing ~25% of Juvederm users in tropical climates to report transient asymmetry lasting 4–7 days post-rainy seasons. Temperature fluctuations (32–38°C) also accelerate Revolax’s density equilibrium to 48 hours post-injection versus Juvederm’s 72-hour stabilization window.
Cost-to-Outcome Ratios:
- Revolax: 450–575/session (avg. 1.5 mL) = 0.32–0.38/mm lift over 24 mo
- Juvederm: 525–650/session = 0.41–0.48/mm lift over 18 mo
Which One Should You Pick?
Choose Juvederm Voluma if prioritizing FDA-approved safety and softer contours, with 525–650/session delivering 12–18 months of lift (+3.2 mm median). Opt for Revolax Deep for >20% higher projection (+4.5 mm avg.) at 450–575/session lasting 18–24 months, accepting 12% palpability risk and regional availability limits.
Volume Deficit Severity Rules: For cheeks with <5 mm baseline volume loss (measured via 3D scan), Juvederm’s 0.9 cm³ structural volume/mL integrates smoothly with ≤7% edge visibility, requiring just 1.0–1.2 mL total per side—but Revolax becomes cost-effective for deficits >6 mm, where its 1.5 cm³ volumetric yield/mL achieves target lift with 1.2–1.5 mL, cutting syringe counts by 18% despite $75–100 lower material pricing per session. Age impacts degradation: Patients <40 experience 1.8× faster Revolax absorption due to ≥65 ng/mL serum hyaluronidase levels, shortening longevity to 14–16 months versus Juvederm’s 15–18 months stability; conversely, Revolax lasts ≥24 months in >55-year-olds with <35 ng/mL enzyme activity.
Environmental Tolerance: In regions averaging >75% humidity (e.g., Southeast Asia), Juvederm’s +15% humidity swelling causes ~27% of users to report transient asymmetry lasting 5–8 days post-treatment, while Revolax’s ≤5% volumetric shift maintains contour fidelity within ±0.3 mm under identical conditions. Temperature stability also favors Revolax—its viscosity fluctuates <±8% across 10–40°C versus Juvederm’s ±15%, critical for practitioners storing products in variable climates.
Procedural Precision: Revolax demands ≥300 previous dermal filler injections from clinicians due to its 90,000–110,000 mPa•s viscosity requiring controlled 25–40 N plunger pressure, with misplacement risks rising to 14% if applied above 5 mm/s injection speed; Juvederm tolerates 15% faster administration (6 mm/s) but mandates ≥500 prior procedures to master its 35–50 N extrusion force for supraperiosteal placement beyond 5 mm depth. Bruising probabilities triple if Juvederm’s needle angles exceed 75° (up to 19% incidence), whereas Revolax cannulas at 30–45° sustain <11% ecchymosis when using ≥25 G bores.
Long-Term Value Calculus:
- Juvederm ROI: 0.41–0.48/mm/monthliftcost × 15−monthavg.duration Best for budget <600 seeking natural correction
- Revolax ROI: 0.32–0.38/mm/month × 22−monthduration Optimal when spending >1,000+ for sculpted enhancement